Safety of Hydronidone Capsules for Liver Scarring and Cirrhosis
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests a new medication called Hydronidone for people with liver scarring (fibrosis) or cirrhosis. It aims to see if the drug is safe and may help slow or improve the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver scarring (hepatic fibrosis) or cirrhosis, proven by a liver biopsy or imaging test (like Fibroscan or ultrasound) within the last 3 months to 1 year.
- Your liver enzymes (ALT) are less than 8 times the normal upper limit.
- You are not pregnant, and if you could become pregnant, you agree to use effective birth control during the study and for 6 months after.
- You have not had major stomach or intestinal bleeding in the past 3 months, and you do not have a history of liver cancer or a very high risk of it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a long-term treatment called hydronidone for liver scarring (fibrosis) caused by chronic hepatitis B. It aims to see if the treatment can help slow or reverse liver damage in people who are already on antiviral therapy or starting treatment for the first time.
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
This study tests how a drug called hydronidone is processed and removed from the body using a very small amount of radioactive labeling. It helps researchers understand how the drug works, so it may lead to better treatments for conditions like liver fibrosis.
This trial tests a new medicine called Hydronidone Capsule in healthy people to see how the body processes it and whether it is safe. If you are in good health, you may be able to join this first-in-human study.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.
Hear when a new Chronic Hepatitis B With Hepatic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.